Dosing Options for Olmesartan/HCTZ and Micardis HCT
Olmesartan/HCTZ (Benicar HCT) is available in three fixed-dose combinations: 20/12.5 mg, 40/12.5 mg, and 40/25 mg, while Micardis HCT (telmisartan/HCTZ) is available in 40/12.5 mg, 80/12.5 mg, and 80/25 mg combinations. 1, 2
Olmesartan/HCTZ (Benicar HCT) Dosing
The available fixed-dose combinations are:
- 20 mg olmesartan/12.5 mg HCTZ
- 40 mg olmesartan/12.5 mg HCTZ
- 40 mg olmesartan/25 mg HCTZ
All formulations are dosed once daily 1
Micardis HCT (Telmisartan/HCTZ) Dosing
The available fixed-dose combinations are:
- 40 mg telmisartan/12.5 mg HCTZ
- 80 mg telmisartan/12.5 mg HCTZ
- 80 mg telmisartan/25 mg HCTZ
All formulations are dosed once daily and may be taken with or without food 2
Practical Titration Strategy
Starting approach: Begin with the lower-dose combination (olmesartan 20/12.5 mg or telmisartan 40/12.5 mg) in most patients, particularly those new to combination therapy 2
Titration timeline: Assess blood pressure response after 2-4 weeks. If BP remains uncontrolled, uptitrate to the next strength 2, 3
Maximum doses:
- Olmesartan/HCTZ: 40/25 mg once daily
- Telmisartan/HCTZ: 80/25 mg once daily (can be increased to 160/25 mg using two 80/12.5 mg tablets, though this exceeds standard fixed-dose combinations) 2
Special Populations
Renal impairment: Use standard regimens if creatinine clearance >30 mL/min. For CrCl <30 mL/min, loop diuretics are preferred over thiazides, making these combinations inappropriate 2
Hepatic impairment: Not recommended in severe hepatic impairment. In mild-to-moderate hepatic insufficiency or biliary obstruction, initiate with the lowest dose combination (olmesartan 40/12.5 mg or telmisartan 40/12.5 mg) under close supervision 2
Elderly patients (≥65 years): Standard dosing applies. Studies demonstrate safety and efficacy across all age groups, including those ≥80 years, with no increased risk of hypotension-related adverse events 4, 5
Clinical Efficacy Data
Research demonstrates that olmesartan/HCTZ combinations produce substantial BP reductions. The 40/25 mg combination achieves mean reductions of approximately 26.8/21.9 mmHg from baseline, with BP goal rates (<140/90 mmHg) reaching 56-88% depending on baseline severity 3, 6, 4. Adding HCTZ 12.5 mg to olmesartan 40 mg monotherapy provides an additional 3.1 mmHg reduction in diastolic BP compared to monotherapy alone 3.